Brought to you by 
AbbVie pays $63bn in cash and stock for Allergan
08 May 2020
Executive Summary
AbbVie Inc. is buying Allergan PLC for an equity value of $63bn in cash and stock. Allergan shareholders will receive $188.24 per share ($120.30 in cash and 0.8660 AbbVie shares (worth $67.94)).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Topical Delivery
- Transdermal
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com